Edward Gillis - BioCardia Senior Devices
Executive
Edward Gillis is Senior Devices of BioCardia
| Age | 62 |
| Phone | 650 226 0120 |
| Web | https://www.biocardia.com |
Edward Gillis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Edward Gillis against BioCardia stock is an integral part of due diligence when investing in BioCardia. Edward Gillis insider activity provides valuable insight into whether BioCardia is net buyers or sellers over its current business cycle. Note, BioCardia insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioCardia'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Edward Gillis over six months ago Disposition of 30000 shares by Edward Gillis of BioCardia at 2.49 subject to Rule 16b-3 |
BioCardia Management Efficiency
The company has return on total asset (ROA) of (1.3267) % which means that it has lost $1.3267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.0362) %, meaning that it generated substantial loss on money invested by shareholders. BioCardia's management efficiency ratios could be used to measure how well BioCardia manages its routine affairs as well as how well it operates its assets and liabilities. BioCardia (BCDAW) is traded on NASDAQ Exchange in USA and employs 16 people.Management Performance
| Return On Equity | -7.04 | |||
| Return On Asset | -1.33 |
BioCardia Leadership Team
Elected by the shareholders, the BioCardia's board of directors comprises two types of representatives: BioCardia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioCardia. The board's role is to monitor BioCardia's management team and ensure that shareholders' interests are well served. BioCardia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioCardia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Altman, President CEO | ||
| Edward Gillis, Senior Devices | ||
| Sujith Shetty, Chief Regulatory | ||
| Sujith MBBS, Chief Regulatory | ||
| David McClung, Chief Officer |
BioCardia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioCardia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.04 | |||
| Return On Asset | -1.33 | |||
| Operating Margin | (41.36) % | |||
| Number Of Shares Shorted | 4.26 K | |||
| Revenue | 477 K | |||
| EBITDA | (11.23 M) | |||
| Net Income | (11.57 M) | |||
| Total Debt | 1.31 M | |||
| Book Value Per Share | (1.27) X | |||
| Cash Flow From Operations | (9.97 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in BioCardia Stock
If you are still planning to invest in BioCardia check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioCardia's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |